Abstract:BACKGROUND:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in tumor cells, but when used alone, it is not effective in the treatment of TRAIL-resistant tumors. Some studies have shown that gefitinib interacts with recombinant mutant human TRAIL (rmhTRAIL) to induce high levels of apoptosis in gefitinib-responsive bladder cancer cell lines; however, the molecular mechanisms underlying the anticancer effects are not fully understood. Several reports have shown that the death receptor 5 (DR5) plays an important role in sensitizing cancer cells to apoptosis induced by TRAIL. Therefore, we investigated the effects of the combination of drugs and the expression of the DR5 to analyze the growth of a gefitinib-responsive non-small cell lung cancer cell line PC9, which was treated with rmhTRAIL and gefitinib individually or in combination.METHODS:Human PC9 non-small cell lung cancer cells harboring an epidermal growth factor receptor mutation were used as a model for the identification of the therapeutic effects of gefitinib alone or in combination with rmhTRAIL, and cytotoxicity was assessed by MTT assays. Cell cycle and apoptosis were investigated using flow cytometry. Moreover, the effects of drugs on DR5, BAX, FLIP, and cleaved-caspase3 proteins expressions were analyzed using Western blot analyses. Finally, quantitative polymerase chain reaction analysis was carried out to assess whether rmhTRAIL and gefitinib modulate the expression of genes related to drug activity.RESULTS:Gefitinib and rmhTRAIL synergistically interact to inhibit cell proliferation, and apoptosis assessment demonstrated that associations of drug increased the apoptotic index. rmhTRAIL when used alone downregulated DR5 and upregulated BAX, FLIP, and cleaved-caspase3 proteins expressions. However, results obtained in Western blot analyses demonstrated that the combined treatment-induced cell apoptosis was achieved involving upregulated DR5, cleaved-caspase3, and BAX proteins expression and downregulated FLIP protein expression. Moreover, quantitative polymerase chain reaction showed that gefitinib modulated the expression of targets related to rmhTRAIL activity.CONCLUSION:These results indicate that epidermal growth factor receptor inhibitors enhance rmhTRAIL antitumor activity in the gefitinib-responsive PC9 cell line, and upregulated DR5 expression plays a critical role in activating caspase-signaling apoptotic pathway.

Anti-DR5 monoclonal antibody enhances cisplatin-inducing apoptosis of HeLa cells

Cisplatin Induces Apoptosis of Hepatocellular Carcinoma LM3 Cells Via Down-Regulation of XIAP.

Changes and Significance of Fas and Cflip in Apoptosis of Human Rhabdomyosarcoma Cells Induced by Combination of TRAIL and Cisplatin

ATF5 increases cisplatin-induced apoptosis through up-regulation of cyclin D3 transcription in HeLa cells.

DAP5 ameliorates cisplatin-induced apoptosis of renal tubular cells.

Effects of TRAIL combined with cisplatin on Hep-2 laryngeal squamous carcinoma in vitro

The mechanism of cisplatin-induced apoptosis in HeLa cells

The Apoptotic Pathway of Laryngeal Squamous Carcinoma Cell Line Induced by Combined TRAIL with Chemotherapeutic Drugs or Radiotherapy

[Synergistic Effects and Mechanisms of Combined Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Chemotherapeutic Drugs or Radiotherapy in Killing Laryngeal Squamous Carcinoma Cells in Vitro].

TR4 Nuclear Receptor Enhances the Cisplatin Chemo-Sensitivity Via Altering the ATF3 Expression to Better Suppress HCC Cell Growth

Nuclear proteome analysis of cisplatin-treated HeLa cells

Experimental Study on the Synergistic Anti- Cervical Cancer Effect of Disulfiram and Cisplatin Via Endoplasmic Reticulum Stress

Calcium efflux from the endoplasmic reticulum regulates cisplatin-induced apoptosis in human cervical cancer HeLa cells

Transfection of PDCD5 Effect on the Biological Behavior of Tumor Cells and Sensitized Gastric Cancer Cells to Cisplatin-Induced Apoptosis

Antisense oligodeoxynucleotide targeting chk1 increases sensitivity of HeLa cells to apoptosis induced by DDP

Gefitinib Upregulates Death Receptor 5 Expression to Mediate Rmhtrail-Induced Apoptosis in Gefitinib-sensitive NSCLC Cell Line.

Effect of LGR5 knockdown by shRNA on the proliferation and drug resistance of HeLa cells

The Characteristic of an Anti-Human DR5 Antibody A6

Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway

Cisplatin-mediated c-myc overexpression and cytochrome c (cyt c) release result in the up-regulation of the death receptors DR4 and DR5 and the activation of caspase 3 and caspase 9, likely responsible for the TRAIL-sensitizing effect of cisplatin

Apoptosis of HeLa Cells Induced by Cisplatin and Its Mechanism